Articles

Dive into our comprehensive collection of pharma and healthcare articles for expert analysis, strategic insights, and emerging trends across R&D, market access, digital health, and regulatory science — curated to inform, inspire, and empower your next move.

October 21, 2026

The Evolution of PD-1/PD-L1: From Immune Checkpoint Breakthrough to What Comes After Keytruda

The protein was named for the wrong job. In 1992,…

October 20, 2026

Gorlin Syndrome Treatment Burden Problem: What the Patidegib Readout Could Change

Patients with severe Gorlin syndrome can face repeated surgeries year…

October 8, 2026

Forecasting Rare Disease Markets: Why Small Patient Populations Demand a More Rigorous Model

Rare disease markets have an odd commercial paradox built into…

October 3, 2026

What’s Driving R&D in Triple-Negative Breast Cancer

For years, chemotherapy was the backbone of triple-negative breast cancer…

October 1, 2026

Beyond the Static Document: Why Evidence-Driven TPP Optimization Is Becoming a Strategic Imperative in Pharma

Every drug development program starts with a hypothesis about the…

September 24, 2026

Primary Market Research in Pharma: Turning Stakeholder Perspectives into Actionable Decisions

In pharma, more data doesn't always mean better answers.Secondary research…

September 15, 2026

The Evolution of HEOR in Rare Diseases: From Cost-Effectiveness to Strategic Market Access

There used to be a simple rule in pharma: scientists…

September 7, 2026

HER2-Positive Metastatic Breast Cancer: The Treatment Shift Reshaping the Market

A Decade of Reinvention There was a time when a…